vs
化石集团（FOSL）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
化石集团的季度营收约是Orthofix Medical Inc.的1.2倍（$270.2M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -14.8%，领先13.8%），Orthofix Medical Inc.同比增速更快（2.0% vs -21.1%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-22.5M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -11.4%）
化石集团是1984年成立的美国时尚设计制造企业，总部位于得克萨斯州理查森。集团旗下拥有Fossil、Relic、Michele Watch、Skagen、Zodiac Watches等多个品牌，同时也为宝马、彪马、阿玛尼、迈克高仕、DKNY等多个知名品牌代工生产授权配饰。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FOSL vs OFIX — 直观对比
营收规模更大
FOSL
是对方的1.2倍
$219.9M
营收增速更快
OFIX
高出23.0%
-21.1%
净利率更高
OFIX
高出13.8%
-14.8%
自由现金流更多
OFIX
多$39.3M
$-22.5M
两年增速更快
OFIX
近两年复合增速
-11.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $270.2M | $219.9M |
| 净利润 | $-40.0M | $-2.2M |
| 毛利率 | 49.0% | 71.1% |
| 营业利润率 | -8.0% | 0.2% |
| 净利率 | -14.8% | -1.0% |
| 营收同比 | -21.1% | 2.0% |
| 净利润同比 | -257.8% | 92.4% |
| 每股收益（稀释后） | $-0.76 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FOSLOFIX
| Q4 25 | $270.2M | $219.9M | ||
| Q3 25 | $220.4M | $205.6M | ||
| Q2 25 | $233.3M | $203.1M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | $342.3M | $215.7M | ||
| Q3 24 | $287.8M | $196.6M | ||
| Q2 24 | $260.0M | $198.6M | ||
| Q1 24 | $254.9M | $188.6M |
净利润FOSLOFIX
| Q4 25 | $-40.0M | $-2.2M | ||
| Q3 25 | $-2.1M | $-22.8M | ||
| Q2 25 | $-17.9M | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | $-11.2M | $-29.1M | ||
| Q3 24 | $-31.9M | $-27.4M | ||
| Q2 24 | $-38.8M | $-33.4M | ||
| Q1 24 | $-24.3M | $-36.0M |
毛利率FOSLOFIX
| Q4 25 | 49.0% | 71.1% | ||
| Q3 25 | 57.5% | 72.2% | ||
| Q2 25 | 61.3% | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | 53.9% | 69.0% | ||
| Q3 24 | 49.4% | 68.7% | ||
| Q2 24 | 52.6% | 67.8% | ||
| Q1 24 | 52.4% | 67.5% |
营业利润率FOSLOFIX
| Q4 25 | -8.0% | 0.2% | ||
| Q3 25 | 3.9% | -8.3% | ||
| Q2 25 | -2.9% | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | -4.8% | -5.3% | ||
| Q3 24 | -8.5% | -9.6% | ||
| Q2 24 | -13.1% | -12.5% | ||
| Q1 24 | -11.5% | -15.6% |
净利率FOSLOFIX
| Q4 25 | -14.8% | -1.0% | ||
| Q3 25 | -1.0% | -11.1% | ||
| Q2 25 | -7.7% | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | -3.3% | -13.5% | ||
| Q3 24 | -11.1% | -13.9% | ||
| Q2 24 | -14.9% | -16.8% | ||
| Q1 24 | -9.5% | -19.1% |
每股收益（稀释后）FOSLOFIX
| Q4 25 | $-0.76 | $-0.05 | ||
| Q3 25 | $-0.04 | $-0.57 | ||
| Q2 25 | $-0.33 | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | $-0.15 | $-0.76 | ||
| Q3 24 | $-0.60 | $-0.71 | ||
| Q2 24 | $-0.73 | $-0.88 | ||
| Q1 24 | $-0.46 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $79.2M | $82.0M |
| 总债务越低越好 | $169.1M | — |
| 股东权益账面价值 | $112.6M | $450.0M |
| 总资产 | $701.0M | $850.6M |
| 负债/权益比越低杠杆越低 | 1.50× | — |
8季度趋势，按日历期对齐
现金及短期投资FOSLOFIX
| Q4 25 | $79.2M | $82.0M | ||
| Q3 25 | $109.9M | $62.9M | ||
| Q2 25 | $78.3M | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | $123.6M | $83.2M | ||
| Q3 24 | $106.3M | $30.1M | ||
| Q2 24 | $104.9M | $26.4M | ||
| Q1 24 | $112.9M | $27.0M |
总债务FOSLOFIX
| Q4 25 | $169.1M | — | ||
| Q3 25 | $165.6M | $157.2M | ||
| Q2 25 | $167.2M | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $162.7M | $157.0M | ||
| Q3 24 | $173.4M | $118.5M | ||
| Q2 24 | $156.5M | $118.0M | ||
| Q1 24 | $202.9M | $118.2M |
股东权益FOSLOFIX
| Q4 25 | $112.6M | $450.0M | ||
| Q3 25 | $150.3M | $442.5M | ||
| Q2 25 | $140.6M | $458.3M | ||
| Q1 25 | — | $458.3M | ||
| Q4 24 | $148.7M | $503.1M | ||
| Q3 24 | $164.4M | $525.9M | ||
| Q2 24 | $189.6M | $546.0M | ||
| Q1 24 | $229.1M | $570.3M |
总资产FOSLOFIX
| Q4 25 | $701.0M | $850.6M | ||
| Q3 25 | $704.5M | $832.6M | ||
| Q2 25 | $686.0M | $837.2M | ||
| Q1 25 | — | $823.1M | ||
| Q4 24 | $763.6M | $893.3M | ||
| Q3 24 | $812.4M | $867.9M | ||
| Q2 24 | $785.7M | $882.0M | ||
| Q1 24 | $891.0M | $906.0M |
负债/权益比FOSLOFIX
| Q4 25 | 1.50× | — | ||
| Q3 25 | 1.10× | 0.36× | ||
| Q2 25 | 1.19× | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 1.09× | 0.31× | ||
| Q3 24 | 1.06× | 0.23× | ||
| Q2 24 | 0.83× | 0.22× | ||
| Q1 24 | 0.89× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-22.5M | $16.8M |
| 自由现金流率自由现金流/营收 | -8.3% | 7.6% |
| 资本支出强度资本支出/营收 | 0.1% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-46.0M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FOSLOFIX
| Q4 25 | $-22.2M | $27.7M | ||
| Q3 25 | $9.4M | $12.4M | ||
| Q2 25 | $-60.4M | $11.6M | ||
| Q1 25 | — | $-18.4M | ||
| Q4 24 | $30.5M | $23.7M | ||
| Q3 24 | $-22.8M | $11.7M | ||
| Q2 24 | $38.4M | $9.0M | ||
| Q1 24 | $622.0K | $-18.6M |
自由现金流FOSLOFIX
| Q4 25 | $-22.5M | $16.8M | ||
| Q3 25 | $8.6M | $2.5M | ||
| Q2 25 | $-60.6M | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | $28.5M | $15.2M | ||
| Q3 24 | $-24.1M | $6.3M | ||
| Q2 24 | $36.6M | $-360.0K | ||
| Q1 24 | $-1.1M | $-29.1M |
自由现金流率FOSLOFIX
| Q4 25 | -8.3% | 7.6% | ||
| Q3 25 | 3.9% | 1.2% | ||
| Q2 25 | -26.0% | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | 8.3% | 7.0% | ||
| Q3 24 | -8.4% | 3.2% | ||
| Q2 24 | 14.1% | -0.2% | ||
| Q1 24 | -0.4% | -15.4% |
资本支出强度FOSLOFIX
| Q4 25 | 0.1% | 4.9% | ||
| Q3 25 | 0.4% | 4.8% | ||
| Q2 25 | 0.1% | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | 0.6% | 4.0% | ||
| Q3 24 | 0.4% | 2.7% | ||
| Q2 24 | 0.7% | 4.7% | ||
| Q1 24 | 0.7% | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOSL
| Transferred At Point In Time | $109.7M | 41% |
| Traditional Watches | $91.3M | 34% |
| Other | $50.8M | 19% |
| Leathers | $9.5M | 4% |
| Jewelry | $4.0M | 1% |
| Smartwatches | $3.3M | 1% |
| Products Other | $1.6M | 1% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
